BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of various products for female sexual health and oncology. It provides LibiGel, a transdermal testosterone gel that is in Phase III clinical development for the treatment of female sexual dysfunction; and male testosterone gel for the treatment of hypogonadism in men, which is licensed to Teva Pharmaceuticals USA, Inc. The company also offers various cancer vaccines, which are in Phase I and Phase II clinical trials for the treatment of melanoma, leukemia, pancreatic, breast, and prostate cancer; The Pill-Plus, which is in Phase II clinical trials is a combination of estrogens, progestogens, and androgens to prevent testosterone deficiency; and Elestrin, a food and drug administration approved product for the treatment of hot flashes associated with menopause. BioSante Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Lincolnshire, Illinois.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for BPAX